|Bid||7.85 x 900|
|Ask||9.83 x 800|
|Day's Range||8.25 - 8.63|
|52 Week Range||6.94 - 26.30|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 08, 2023 - Mar 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.60|
Subscribe to Yahoo Finance Plus to view Fair Value for DSGN
Investors who take an interest in Design Therapeutics, Inc. ( NASDAQ:DSGN ) should definitely note that the Independent...
DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment of Fuchs Endothelial Corneal Dystrophy Administered as an Eye Drop; IND Expected in 2023 Advancing Myotonic Dystrophy Type-1 GeneTACTM Lead Molecules; IND Expected in 2024 Conference Call to be Held Today at 4:30pm ET CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nas
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...